Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol®), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys

Oncology

Volumn 67, Issue 3-4, 2004, Pages 187-193

  Bachy, Christine M ^a   Fazenbaker, Christine A ^a   Kifle, Gizachew ^a   McCarthy, Michael P ^a   Cassatt, David R ^a  

^a MEDIMMUNE   (United States)

Author keywords

Amifostine; Intravenous route; Monkeys; Pharmacokinetics; Radiotherapy; Subcutaneous route

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; ELECTROCHEMISTRY; FLUORESCENCE; MACACA; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AMIFOSTINE; ANIMALS; BIOLOGICAL AVAILABILITY; HALF-LIFE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MACACA FASCICULARIS; MERCAPTOETHYLAMINES; RADIATION-PROTECTIVE AGENTS; TISSUE DISTRIBUTION;

EID: 9244228026     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081316     Document Type: Article

References (22)

1. Culy CR, Spencer CM: Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome (review). Drugs 2001;61:641-684.
2. Grdina DJ, Kataoka Y, Murley JS: Amifostine: Mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact 2000;16:237-279.
3. Bonner HS, Shaw LM: New dosing regimens for amifostine: A pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 2002;42:166-174.
4. Anne PR, Curran WJ Jr: A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002;12:18-19.
5. Capizzi RL: The preclinical basis for broadspectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999;26:3-21.
6. Giatromanolaki A, Sivridis E, Maltezos E, et al: Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol 2002;29:14-21.
7. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM: Subcutaneous administration of amifostine (Ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Biol Phys 2003;57:794-802.
8. Swynnerton NF, Huelle BK, Mangold DJ, et al: A method for the combined measurement of ethiofos and WR-1065 in plasma: Application to pharmacokinetic experiments with ethiofos and its metabolites. Int J Radiat Oncol Biol Phys 1986;12:1495-1499.
9. Geary RS, Swynnerton NF, Miller MA, et al: Intraduodenal administration of ethiofos (WR-2721): Dose proportionality study in the rhesus monkey. Res Commun Chem Pathol Pharmacol 1989;65:147-159.
10. Cassatt DR, Fazenbaker CA, Bachy CM, et al: Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol 2002;12:97-102.
11. Wyatt I, Moore RB, Smith LL: Competition for polyamine uptake into rat lung slices by WR2721 and analogues. Int J Radiat Biol 1989;55:463-472.
12. Bonner HS, Shaw LM: Measurement of both protein-bound and total S-2-(3-aminopropylamino) ethanethiol (WR-1065) in blood by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000;739:357-362.
13. Shaw LM, Bonner HS, Brown DQ: Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 1994;22:895-902.
14. Shaw LM, Bonner H, Lieberman R: Pharmacokinetic profile of amifostine. Semin Oncol 1996;23:18-22.
15. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-3345.
16. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)- ethylphosphorothioic acid. Cancer Res 1980;40:1519-1524.
17. Washburn LC, Rafter JJ, Hayes RL: Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat Res 1976;66:100-105.
18. Calabro-Jones PM, Aguilera JA, Ward JF, et al: Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 1988;48:3634-3640.
19. Grdina DJ, Shigematsu N, Dale P, et al: Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995;16:767-774.
20. Shaw LM, Bonner HS, Schuchter L, et al: Pharmacokinetics of amifostine: Effects of dose and method of administration. Semin Oncol 1999;26:34-36.
21. Newton GL, Aguilera JA, Kim T, et al: Transport of aminothiol radioprotectors into mammalian cells: Passive diffusion versus mediated uptake. Radiat Res 1996;146:206-215.
22. Quinones HI, List AF, Gerner EW: Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives. Clin Cancer Res 2002;8:1295-1300.